Ivermectin has been reported to be a SARS-CoV-2 inhibitor. This activity is believed to be due to the dependence of many different RNA viruses on IMPα / β1 during infection. These reports suggested that the inhibitory activity of ivermectin nuclear transport may be effective against SARS-CoV-2, since they demonstrate that ivermectin has antiviral action against the clinical isolate of SARS-CoV-2 in vitro, with a single dose capable to control viral replication in 24-48 hours. in vitro

Severe Acute Respiratory Syndrome

Ventilation Pneumonitis

Ivermectin 5 MG/ML

Hospital Eurnekian

IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of Covid 19

EVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19

Considering healing and/or reducing symptoms and severity of initial presentation

Keeping the patient(s) out of ICU, as they do not need mechanical ventilation and/or special intensive care

potential need of reducing or augmenting doses

Outcome of adverse effects to one or more drugs used in the clinical trial

Personal data will remain secret. Only clinical descriptions (age, gender, co-morbidities, evolution, outcomes will be released

Hector E Carvallo

Principal investigator

Eurnekian Public Hospital

The intervention group will be offered participation for 6 months in a Virtual Communities of practice based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.

The control group will not receive any specific intervention. They receive usual care according to actually clinical practice guidelines.

Ischemic Heart Disease Chronic

based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.

Virtual Communities of practice

Sofía Garrido elustondo

Effectiveness and Cost-effectiveness of a VCoP to Empowerment of Patients With Ischaemic Heart Disease in PHC: Cluster-RCT

Effectiveness and Cost-effectiveness of a Virtual Intervention (VCoP) to Improve the Empowerment of Patients With Ischaemic Heart Disease in Primary Care: Cluster Randomized Controlled Trial

It has 13 items, measured with a Likert scale (from 1 to 4). This questionnaire values activation in patients with chronic diseases. It evaluates people's knowledge and skills in self-care. Puntuation is 0 to 100 (best puntuation)

Data will be collected from self-reported questionnaires and the electronic medical records.

Sofia Garrido Elustondo

Epidemiologist

Gerencia de Atención Primaria, Madrid

Avedis Donabedian Research Institute

Servicio Canario de Salud

Design: pragmatic randomized controlled trial, with two parallel arms, multicenter, 18 months of follow-up
Setting Primary Care Centres belonging to the Autonomous Communities of Catalonia, (329), Madrid (262) and the Canary Islands (102).

Investigator and outcomes Assessor don´t Know the intervention assigned to each patient

Participant is administered acetylsalicylic acid one hour prior to exercise.

Participant is administered placebo one hour prior to exercise.

Participant is administered acetylsalicylic acid, an intervention to improve exercise performance (i.e., increase time to exhaustion) one hour prior to exercise.
Acetylsalicylic acid: 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
Placebo Oral capsule: Placebo capsule is administered one hour prior to exercise

Acetylsalicylic Acid at 1st Visit, Then Placebo at 2nd Visit

Participant is administered placebo one hour prior to exercise.
Acetylsalicylic acid: 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
Placebo Oral capsule: Placebo capsule is administered one hour prior to exercise

Placebo at 1st Visit, Then Acetylsalicylic Acid at 2nd Visit

Total

Sex: Female, Male

Race and Ethnicity Not Collected

Region of Enrollment

Self-report heat-sensitivity during exercise

The measure of interest is the length of time (in seconds) spent exercising at each session. This time has no pre-set upper limit, i.e. patients are free to exercise as long as they wish. This means that the time will not be censored. However, please note that healthy adults' time to exhaustion is approximately 12 minutes.

Acetylsalicylic Acid

Placebo Oral Capsule

Change in Time to Exhaustion

Measure of interest is increase in body temperature from pre- to post-exercise test in each treatment condition (ASA vs. placebo)

650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise

Placebo capsule is administered one hour prior to exercise

Exercise-induced Body Temperature Increase

Within-subjects design
Participant is administered acetylsalicylic acid, an intervention to improve exercise performance (i.e., increase time to exhaustion) one hour prior to exercise.
Acetylsalicylic acid: 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
Placebo Oral capsule: Placebo capsule is administered one hour prior to exercise
First intervention: 1 day; washout period: 1 week; second intervention: 1 day

Acetylsalicylic Acid at 1st Visit Then Placebo at 2nd Visit

Within-subjects design
Participant is administered placebo one hour prior to exercise.
Acetylsalicylic acid: 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
Placebo Oral capsule: Placebo capsule is administered one hour prior to exercise
First intervention: 1 day; washout period: 1 week; second intervention: 1 day

Placebo at 1st Visit Then Acetylsalicylic Acid at 2nd Visit

Overall Study

Victoria M. Leavitt

Fatigue

Overheating

650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise; Placebo oral capsule is administered one hour prior to exercise

Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit

Placebo oral capsule is administered one hour prior to exercise; 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise

Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit

Columbia University Medical Center, MS Center

Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis

A Placebo-controlled Double Blind Crossover Trial of Acetylsalicylic Acid as a Pre-treatment for Exercise in Multiple Sclerosis

Assistant Professor of Neuropsychology

Columbia University

National Multiple Sclerosis Society

Design is a within-subject crossover placebo-controlled experiment. Each participant will be seen for two exercise sessions (stationary cycling) on two days separated by one week, and will receive either ASA or placebo (treatment) at each session prior to commencing exercise. Order of treatment will be randomized and counter-balanced. As such, each participant will serve as his/her own control.

Blinding will be overseen by the CUMC pharmacy; randomization schedule will be submitted to the pharmacy by a third party who is not involved in the study (i.e., non-study personnel). Study investigators will remain blinded until data collection is complete and data have been analyzed.

Ruxolitinib will be administered orally at a dose of 10 mg twice daily (both PV and ET) for two consecutive years.

BAT may include all currently used treatment options. BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc). BAT will be administrated for two consecutive years.

Polycythemia Vera (PV)

Essential Thrombocythemia (ET)

Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.

Ruxolitinib

BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).

Universitätsmedizin Mannheim III. Medizinische Klinik Hämatologie und Internistische Onkologie

Universitätsklinikum Ulm Klinik für Innere Medizin III

Rems-Murr Klinikum Winnenden

Studienzentrum Aschaffenburg

III. Medizinischen Klinik des Klinikums rechts der Isar der TU München

Klinikum Nürnberg Nord Medizinische Klinik 5

Universitätsmedizin Mainz III. Medizinische Klinik und Poliklinik

Universitätsklinikum Bonn Medizinische Klinik und Poliklinik III

Johanniter-Krankenhaus Rheinhausen GmbH Hämatologie / Internistische Onkologie / Tagesklinik

Universitätsklinikum Düsseldorf Klinik für Hämatologie, Onkologie und Klinische Immunologie

Universitätsklinikum Essen Klinik für Hämatologie

Mühlenkreiskliniken Johannes Wesling Klinikum Minden Klinik für Hämatologie, Onkologie und Palliativmedizin

Zentralklinikum Medizinische Klinik A Hämatologie, Hämostaseologie, Onkologie und Pneumologie

Marienhospital

Zentrum für ambulante Hämatologie und Onkologie (ZAHO)

Uniklinik RWTH Aachen

InVO - Institut für Versorgungsforschung in der Onkologie

Universitätsklinikum Magdeburg

Universitätsklinikum Halle (Saale)

Klinikum Chemnitz gGmbH Klinik für Innere Medizin III

Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I

Charité Universitätsmedizin Berlin Med. Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie

Universitätsklinikum Freiburg - Klinik für Innere Medizin I

Universitätsklinikum Hamburg Eppendorf Klinik und Poliklinik für Onkologie, Hämatologie und KMT mit Sektion Pneumologie

Universitätsklinik Jena - Klinik für Innere Medizin II

Universitätsklinikum Leipzig - Medizinische Klinik und Poliklinik I

UNIVERSITÄTSKLINIKUM Schleswig-Holstein - Klinik für Hämatologie und Onkologie, Campus Lübeck

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial

The rate of complete clinicohematologic response rate (CHR) as defined by Barosi et al Blood 2009

acetylsalicylic acid/fatigue

IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of Covid 19

Effectiveness and Cost-effectiveness of a VCoP to Empowerment of Patients With Ischaemic Heart Disease in PHC: Cluster-RCT

Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht